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Abstract:  
The fervency for advancement and evolution in percutaneous coronary intervention has 
revolutionised the treatment of coronary artery disease. Historically, the focus of the 
interventional cardiologist was directed at the restoration of luminal patency of the major 
epicardial coronary arteries, yet whilst this approach is evolving with a much greater 
utilisation of physiological assessment, it often neglects consideration of the role of the 
coronary microcirculation which has been shown to clearly influence prognosis. In this 
review, we consider exploring the narrative of the coronary circulation as more than just a 
simple conduit for blood but an organ with functional significance. We discuss the 
organisation and physiology of the coronary circulation as well as the current methods and 
techniques used to examine it. We then review the studies exploring coronary artery 
endothelial function, appreciating that coronary artery disease occurs on a spectrum of 
disorder and that percutaneous coronary intervention has a latent effect on the coronary 
circulation with long-term consequences. We conclude that greater recognition of the 
coronary artery endothelium and mechanisms of the coronary circulation should guide 
revascularisation strategies further. 
 
  
3 of 51 
 
List of abbreviations: 
ACH = Acetyl Choline 
ATP = Adenosine Triphosphate 
BMS = Bare Metal Stents 
BVS = Bioresorbable Vascular Scaffolds 
CFR = Coronary Flow Reserve 
CMR = Cardiac Magnetic Resonance Imaging 
CPT = Cold Pressor Testing 
DCB = Drug Coated Balloon  
DES = Drug Eluting Stents 
cGMP = Cyclic Guanosine Monophosphate  
FFR = Fractional Flow Reserve 
HCM = Hypertrophic Cardiomyopathy 
IC = Intra-coronary 
IL-1 = Interleukin 1 Inflammatory Cytokine 
ISR = Instent Restenosis 
IMR = Index of Microvascular Resistance 
LAD = Left Anterior Descending Coronary Artery 
LCx = Left Circumflex Coronary Artery 
NO = Nitric Oxide 
PCI = Percutaneous Coronary Intervention 
PES = Paclitaxel Eluting Stents 
PET = Positron Emission Tomography 
POBA = Plain Old Balloon Angioplasty 
SES = Sirolimus Eluting Stents 
ST = Stent Thrombosis 
TNF alpha = Tumour Necrosis Factor inflammatory cytokine 
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Introduction: 
In 1954, Dr Rudolf Altshul; an anatomist and histologist at the University of Saskatchewan, 
Canada, reviewed the role of the endothelium stating “while working on problems of 
arteriosclerosis, I have realised not only how little I knew about the endothelium, but how 
much I ought to know for the proper understanding of arteriosclerosis”(1) . Decades later, 
there is a consistently evolving appreciation that endothelial function and its disorder are 
critical precursors in the development of atherosclerosis and cardiovascular disease.  Given 
the evidence that endothelial dysfunction has a direct correlation with poor cardiovascular 
outcomes (2–4), we focus this review on the crucial role of the endothelium within the 
coronary circulation, the pathophysiology of endothelial dysfunction and its clinical 
relevance.   
 
Coronary Artery disease – a historical perspective 
The first recorded descriptions of angina in modern history date back to 400 B.C. by 
Hippocrates, who observed that for some patients cold wind could precipitate their chest 
pain(5). The symptom of chest discomfort was linked to exertion by Phillip Melanchton a 
Professor of Greek and theologian who in the early 16th century detailed attacks of “chest 
pains” that had affected his friend Martin Luther(6,7). It was not until 1768 however, that 
the term “angina pectoris” was first used by William Heberden, a renowned physician 
working in London who at the time of presenting his seminal paper “Some account of a 
Disorder of the Breast” used the description: “Those who are afflicted with it, are seized 
while they are walking (more especially if it be uphill, and soon after eating) with a painful 
and most disagreeable sensation in the breast, which seems as if it would extinguish life if it 
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were to increase or to continue; but the moment they stand still, all this uneasiness 
vanishes”(6–8) 
In this famous account; Heberden proposed no explanation as to a possible underlying 
pathophysiology for the phenomena. However, he later received an anonymous letter from 
a physician who; having read the paper, had recognised Heberden’s description as matching 
his own symptomology. The letter went on to request that Heberden perform an autopsy on 
him when he died in order to further understand the disorder. Edward Jenner (best known 
for later introducing vaccination in 1798) performed the autopsy with John Hunter in 1772 
(9), however as there was no recognition for a causal link between angina and coronary 
artery disease at the time, the coronary arteries were not assessed in any detail and so an 
opportunity to record the association was missed (7,8). It was not until 1786 when after 
performing further autopsies on patients with similar symptoms that Jenner wrote in his 
letter to Heberden that coronary artery disease was explicitly linked to angina (10).  
Carl Weigert, a German Pathologist, first proposed that the occlusion of the epicardial 
coronary artery was the cause for Myocardial Infarction in 1880 (11). Subsequently, James 
Herrick’s paper from 1912 “Certain clinical features of sudden obstruction of the coronary 
arteries” popularised the hypothesis. These led to a much greater scrutiny of the coronary 
artery circulation for strategies for diagnosis and treatments of ischaemic heart disease 
(8,10). The management of ischaemic heart disease changed drastically with the 
development of selective coronary angiography in 1958 by Sones, Judkins and Amplatz as a 
method for identifying coronary stenosis and laying the foundation for novel 
treatments(12). The development of coronary artery bypass grafting in the 1960s and 70s by 
Sabiston, Kolesov, Favaoloro and Effler and percutaneous coronary angioplasty  by Andreas 
Gruntzig in 1977 revolutionised the management of coronary artery disease (12–15).  
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However, a significant proportion (40%) of patients with symptoms matching Heberden’s 
classical description of angina, would subsequently be found to have normal coronary artery 
appearances on angiography (13,16,17) indicating that major epicardial coronary stenoses 
account for only part of the disease spectrum. Initial studies involving the close examination 
of canine hearts in the 1960s demonstrated the microscopic aspects of the coronary 
circulation leading to greater recognition of the small vessel circulation (13,18,19). In the 
1980s, there was a proliferation of research directed at the microcirculation of the human 
heart, utilising microscopic video to look at the behaviour and movements of the arterial 
circulation. In 1985, Cannon and Epstein introduced the term “microvascular angina” 
proposing that the symptoms of angina arose from the small intramural pre-arteriolar 
coronary arteries (20,21). There was some appreciation at the time that whilst the epicardial 
circulation was clearly important, there was a significant proportion of patients who were 
significantly debilitated in the longer-term despite angiographically “normal” coronary 
artery appearances (22).  Cannon further went on to explore patients with normal epicardial 
artery appearances via invasive angiography, using a technique that involved the insertion 
of a pigtail catheter in the patient’s left ventricle and a balloon catheter in the pulmonary 
artery, then cannulating the great cardiac vein and invasively monitoring brachial artery 
pressures and calculating the coronary circulatory resistance from the derived values 
(21,23,24). Cannon was able to demonstrate that these patients with anginal symptoms 
developed increases in vascular resistance on response to certain stimuli (in his particular 
study, rapid atrial pacing) compared to those who did not have angina (21,23,24). It was this 
initial work that greatly helped advance recognition of the function of the coronary 
circulation as more than a passive channel for blood to travel to the heart muscle and 
instead a system that elicited physiological responses to various stimuli. 
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The Endothelium and its physiology: 
The coronary artery wall is composed of the functional layer called the endothelial lamina, a 
smooth muscle lamina and a more architectural, supportive connective tissue lamina (see 
Figure 1). The endothelium was initially characterised as a simple cellular barrier separating 
the blood from the interstitial components of the blood vessel but it has since been 
demonstrated to be a selectively permeable, metabolically active regulatory interface 
essential to normal vascular physiology (1,4,25,26). 
[Figure 1- This is an image representation of a cross section through a coronary artery] 
 
Endothelial cells metabolise L-arginine via an endothelial isoform of nitric oxide synthase to 
form nitric oxide (NO). The NO produced by endothelial cells contribute to maintaining 
vascular homeostasis by regulating vasomotor tone (normally resulting in vasodilation) and 
it also serves to inhibit the non-thrombogenic behaviours by acting on platelets and 
leucocytes (see Figure 2). The NO synthesis can be stimulated by receptor dependent 
agonists (acetylcholine and bradykinin) and changes in blood flow. In the unhealthy 
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endothelium, the endothelial nitric oxide synthase can become uncoupled and actually 
inactivate NO as well as encouraging oxidative stress.   
 
 
[Figure 2 – Overview of Endothelial function] An illustration of the processes within the 
endothelium contributing to Vasodilation and Vasoconstriction. ACH Acetylcholine, NO 
Nitric Oxide, M Muscarinic receptors, Enos – NO synthase isomer. ET1 Endothelin 1, TXA2 
Thromboxane A2, ETA Endothelin A Receptor, TP Thromboxane Prostanoid Receptor 
 
The endothelium has a number of different functions which include the synthesis and 
biodegradation of vasoactive substances, buffering of the products of aerobic respiration, 
transport and metabolism of lipoproteins, secretion and enzymatic remodelling of 
extracellular matrix components, modulation of the coagulation cascade, elaboration of 
various growth factors, cytokines and hormone like substances as well as the biosynthesis of 
prostaglandins and other potent autocoids. In addition, endothelial cells perform a 
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reversible adaptive mechanism in response to certain pro inflammatory cytokines or 
bacterial endotoxins as part of a response to infection and inflammation (27–30). 
  
The Functional Anatomy of the Coronary Circulation: 
In order for the heart muscle to generate the ATP necessary for cardiac pump function, it 
requires continuous perfusion with oxygenated blood. The healthy, resting coronary blood 
flow under normal haemodynamic conditions is 0.7-1.0mL/min/g, which is maintained by an 
active and multifactorial homeostatic process (31,32). In response to demand under normal 
circumstances, the coronary circulation can upregulate flow up to five-fold (this potential is 
called “coronary flow reserve”). The Coronary flow reserve (CFR) is a function of the 
coronary circulation that is measurable as a ratio of hyperaemic flow (usually in response to 
an agonist like adenosine or dipyridamole) to basal flow (33). CFR is the net result of the 
vasodilator capacity of the coronary circulation and can be measured through several 
methods including doppler echocardiography and PET (13,16,31,34,35).  
 
Flow is maintained by a process of “autoregulation”, utilising different stimuli: 
• Metabolic regulation in response to myocardial oxygen demand (i.e. the demands of 
the myocardium dictate coronary blood flow) 
• Shear stress – the endothelium is sensitive to the tractive force exerted by the 
velocity and viscosity of blood (36,37) 
• Neural and bio-humoral regulation via the sympathetic and parasympathetic 
nervous system (for example: during exercise) 
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The coronary circulation can be considered as having three major divisions that react to 
different stimuli in a variety of ways. Their “borders” are transitional and whilst difficult to 
define histologically or anatomically, the compartments can be characterised based on 
function; as each compartment is governed by distinct, regulatory mechanisms which alter 
flow (31,38). Conventionally the nomenclature used classifies these divisions as the 
“proximal”, “intermediate” and “distal compartment”.   
The proximal compartment refers to the large, epicardial coronary arteries that are 
delineated during coronary angiography (with a diameter >500µm). These epicardial arteries 
act essentially as capacitance vessels that in the healthy state offer no resistance to flow 
between the aortic and coronary sinus. During systole, the epicardial vessel stretches (with 
its blood volume increasing by up to 25%) generating elastic, potential energy which is then 
converted to kinetic energy during diastole. This capacitance response is an active process 
and modulated by changes in epicardial vessel tone (described as a “vasomotor” response). 
This vasomotor response is maintained via a balance between a degree of vasoconstriction 
(of the smooth muscle layer of the vessel) and vasodilatation (directed by the endothelium). 
This mechanism is in part, the target of anti-anginal therapy that utilises the bioavailability 
and action of nitric oxide (NO) (39,40).  
The intermediate and distal compartments are referred to collectively as the 
microcirculation, which is the major reservoir for the myocardial blood supply containing 
90% of the total myocardial blood volume. The microcirculation behaves in a manner similar 
to the other vascular beds in the body in that it is these vessels that govern resistance to 
perfusion (29,38,41). 
The intermediate compartment is composed of pre-arterioles (diameter 100-500µm) which 
are extra-myocardial vessels that have a thinner endothelial and smoother muscle layer 
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than the epicardial coronary arteries of the proximal compartment. As mentioned, the 
compartments are divided by “transitional zones” rather than clearly demarcated borders 
and as such the proximal segments of the pre-arterioles behave similarly to the epicardial 
arteries in that they are responsive to flow dependent dilatation, whereas distally they 
behave more like the arterioles of the distal compartment in that they are responsive to 
intravascular pressure changes. The intermediate compartment can be distinguished from 
the distal compartment due to its independence from the influence of myocardial 
metabolites.  
The distal compartment is composed of arterioles (diameter <100µm) which have an even 
thinner tunica media (i.e. smooth muscle walls) than the proximal and intermediate 
compartment vessels. Moreover, the smaller, terminal vessels of this compartment may lack 
a vascular smooth muscle layer entirely (replaced by small, unique cells called “pericytes” 
which do have some contractile qualities) and the tunica intima may lack an internal elastic 
membrane as they give rise to the capillary bed (34). When viewed using plastic casting or 
ink injections, these vessels appear highly variable in structure as the capillary network is 
arranged amongst the arterioles and venules (42) These small vessels run parallel to muscle 
fibres. The tone and resistance of the distal compartment is governed by metabolites 
produced by the myocardium and controls flow to the capillary network (34). Capillaries are 
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Disease mechanisms of the coronary circulation and its subtypes: 
It is increasingly understood that disease and disorder of the coronary circulation occurs via 
multiple mechanisms that can be divided into different pathogenic subtypes (3,16,31,43,44).  
Structural abnormalities of the circulation:  
This subtype includes conditions whereby functional luminal diameter is attenuated and can 
be due to luminal stenosis, thrombosis, micro-emboli from percutaneous coronary 
intervention, inherent anomalous coronary vessel anatomy, coronary artery bridges and 
aneurysms. There can also be abnormal remodelling and hypertrophy reducing luminal size 
as a result of hypertension, aging or cardiomyopathic processes(34). This reduction in lumen 
size was demonstrated by Wienike et al (45) to have a direct effect on coronary blood flow 
in a study that involved early uses of the Doppler flow wire and coronary intravascular 
imaging techniques. 
Extravascular changes to the coronary circulation:  
There are various influences external to the vascular circulation.  These include external 
compression, shortened diastolic filling and changes to cardiac metabolism for example 
autonomic dysfunction that follows acute myocardial infarction leading to sympathetic 
overdrive and vasoconstriction (34,46). Complex interactions exist between the autonomic 
nervous system and the blood vessels. The nerve terminal varicosities release 
neurotransmitters which diffuse to and engage vascular cells. Stimulation of the autonomic 
system induces the release of vasoactive mediators such as noradrenaline, adenosine 
triphosphate (ATP) and neuropeptide Y that cause vasoconstriction and acetylcholine and 
calcitonin gene related peptide (CGRP) which cause vasodilatation (47).  
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Systemic, structural changes to the coronary circulation:  
This includes sclerosis, extracellular matrix changes, fibrosis, intramyocardial fat infiltration 
or natural changes such as the aging and the menopause (29,32,43). Patients with systemic 
sclerosis are known to have increased extracellular matrix production leading to the diffuse 
fibrosis of the skin and internal organs which reduces compliance and plasticity with 
impaired remodelling that impedes flow (48). Intramyocardial triglyceride deposits (more 
common in patients with diabetes and obesity) accumulate in the cardiac myocytes causing 
greater LV mass and greater diastolic dysfunction which cause greater cardiac demand and 
work. Intramyocardial triglyceride deposits are also associated with chronic inflammation 
which contributes to atherosclerosis (49). Majerczak et al (50) looked at arterial stiffness 
and endothelial function in young athletes who were followed up into old age and 
demonstrated that despite physical exercise, endothelial function worsened with age  as did 
arterial stiffness. Changes in the vascular matrix (increase in collagen and a decrease in 
elastin), reduced function of vascular smooth muscle and a reduced bioavailability of NO all 
also contribute (31,50). There are also changes that occur in sepsis that cause endothelial 
dysfunction via direct degradation of the endothelium which are associated with worse 
outcomes due to enhanced platelet aggregation and vasoconstriction (51,52).  
 
Functional abnormalities of the coronary circulation (“Vasomotor Function”):  
Vasomotor dysfunction is a disorder of vasomotor function caused by either enhanced 
vasoconstriction, impaired vasodilation (due to endothelium dependent or endothelium 
independent mechanisms) or a combination/imbalance of these. From a clinical perspective, 
as the endothelium governs a significant part of vasomotor function, discussions on 
vasomotor response centres on endothelial function. Endothelial dysfunction is associated 
14 of 51 
 
with conditions that are widely regarded as precursors to atherosclerosis including diabetes, 
obesity and smoking. It is also demonstrable independently of those risk factors without 
obstructive epicardial coronary disease via as yet incompletely understood mechanisms 
(e.g. patients with cardiac syndrome X). Cardiac syndrome X is generally defined for the 
purpose of clinical practice as the presence of angina-like chest discomfort in the absence of 
significant epicardial stenosis; though stricter criteria includes the presence of ST segment 
depression (during anginal episodes), an absence of epicardial coronary artery spasm 
provocation with intracoronary acetylcholine provocation and absence of cardiac or 
systemic diseases associated with microvascular dysfunction (53). Patients with syndrome X 
have been shown to have less intrinsic NO bioavailability and have been shown to have 
greater impairment of endothelium dependent and independent cutaneous microvascular 
function when compared with “normal” controls (17,53,54).  
Hypertrophic cardiomyopathy is known to cause fibrosis and microvascular dysfunction. 
Patterns of fibrosis on Cardiovascular MRI have been shown to have abnormal flow reserve 
(i.e. vasomotor responses) (55). Microvascular dysfunction has a crucial relevance in that is 
thought to be an ischaemic substrate for pathological arrhythmia in itself (29). Furthermore, 
patients at risk of developing HCM have been identified as having endothelial dysfunction 
with abnormal vasomotor responses at young ages (56). 
 
The Physiology of the Normal Endothelium: 
 “Vasomotor function” refers to the vasodilatory or vasoconstrictor responses of the three 
compartments of the coronary circulation to maintain flow (see figure 3) (2,4,21,44). 
Focussed studies on vasomotor activity have shown that the endothelial luminal layer of 
coronary arteries is a crucial, intrinsic element in regulating this process.  




[Figure 3 – Coronary Vascular bed] A schematic representation of the different elements 
and functional significance of the different components of the coronary circulation. CFR 
Coronary Flow Reserve, FFR Fractional Flow Reserve, IFR instantaneous flow reserve, IMR 
Index of microvascular resistance  
 
Vasomotor function can be divided into three main processes (31): 
1) Endothelium dependent vasodilation. The endothelium responds to various 
paracrine factors (including endothelin, serotonin, histamine) which stimulate the 
production of nitric oxide by the endothelium. Nitric oxide binds to guanylyl cyclase 
producing cGMP which causes subsequent vascular smooth muscle relaxation and 
vasodilation of the artery (31,32). This has been demonstrated in studies since the 
1980s, most commonly using acetylcholine or analogues which bind to muscarinic 
receptors and measuring vasomotor responses (61–63). 
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2) Endothelium independent vasodilation. The cell mechanism governing this remains 
incompletely understood (31). Common methods of testing have included the use of 
sodium nitroprusside, papaverine or glyceryl trinitrate to demonstrate smooth 
muscle vasodilation in response to nitric oxide (25,40,43).  (34,64,65)  
3) Vasoconstriction. This is commonly demonstrated with the use of vasopressin in 
studies. Vasopressin has a greater effect on the microcirculation and the wider 
systemic circulation, with only a limited vasoconstrictive effect on the epicardial 
coronary arteries (66,67). Vasoconstriction has been shown to be excessive in 
patients with Diabetes, Takutsubo Cardiomyopathy and Myocarditis perhaps due to 
the upregulation of Vasopressin receptors (66). Vasoconstriction is also considered 
an important component of “no reflow” phenomenon during Primary PCI (26,29,31).  
A coronary circulation with a damaged or absent endothelium demonstrates vasomotor 
function that behaves very differently to a healthy, normal endothelium. These altered 
characteristics are summarised in Table 1 (57–60).  
Normal Endothelium Endothelial Dysfunction 
Vasodilation Vasoconstriction 
Thrombolytic Platelet aggregation 
Anti-inflammatory Inflammation and proliferative 
Biological barrier Increased permeability 
[Table 1 – Roles of the Endothelium] – comparing the effects of a normal functional 
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Endothelial Dysfunction: The role of the endothelium in atherogenesis:  
The term “endothelial dysfunction” refers to the broad alterations in endothelial phenotype 
that may contribute to the clinical expression of atherosclerosis (31,68,69). It can be 
appreciated by measuring vasomotor responses to stimuli and occurs via different 
mechanisms (see Figure 4). Endothelial dysfunction can lead to increased vascular 
permeability to lipoproteins as well as expression of cytokines and adhesion molecules 
which are features of atherosclerosis (1,18,30,32). Furthermore, endothelial dysfunction can 
perpetuate ischaemia as it facilitates smooth muscle wall proliferation and also produces 
substances that promote platelet aggregation (30,70). 
 
[Figure 4 – An illustration of the mechanisms of endothelial dysfunction as a precursor of 
atherosclerosis. Endothelial dysfunction occurs on a spectrum of disorder with 
atherosclerosis and whilst there is a degree of continuity to the process, endothelial 
dysfunction has a role in the development of atheroma at its various stages.  
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Endothelial dysfunction is associated with the loss of intrinsic endothelial vasoprotective 
factors that lead to an imbalance of vasodilation and vasoconstriction with net 
vasoconstriction contributing to the maladaptive vasomotor response. Acetylcholine usually 
elicits NO induced vasodilation though in endothelial dysfunction this is impaired, resulting 
in lower degrees of dilatation, manifesting as lower coronary blood flow or smaller 
reductions in systemic vascular resistance. Acetylcholine also has a direct vasoconstrictor 
effect when acting on smooth muscle cells which is usually masked by the endothelium 
mediated smooth muscle dilatation. In the case of endothelial dysfunction, the vasodilation 
caused by the acetylcholine is attenuated resulting in net vasoconstriction(27,39,60).   
 
The progression of endothelial dysfunction is multifactorial and this occurs as a result of 
various triggers such as shear stress, inflammation and certain clinical states (like diabetes): 
1) Shear Stress  
A common observation in the identification of coronary atheroma is the development of 
lesions in regions which correlate with arterial branch points and other regions of altered 
haemodynamics (1,14,31). In the field of experimental fluid mechanics, specialised devices 
have been used to reconstruct the flow effect over the laminar surface of cultured 
endothelial cell monolayers in vitro. These studies have demonstrated that laminar shear 
induces changes in cell morphology, alignment and cell organisation, suggesting a local risk 
factor for endothelial cell dysfunction in atherogenesis (14,37,71). Diamond et al (72) 
described how shear stress caused transcriptional changes in RNA in cultured human 
endothelial cells which directly affected the fibrinolytic pathways as a response to flow.  
Other studies have confirmed the modulation of DNA in response to haemodynamics. The 
PREDICTION study (70) was a prospective natural history study in Japan which included 
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patients with acute coronary syndrome treated with PCI and reassessed at six month follow 
up with repeat angiography. They measured intravascular flow characteristics to establish 
shear stress and demonstrate a strong association between disturbed endothelial shear 
stresses and subsequent lesion progression.  
 
2) Inflammation: 
Inflammation promotes leucocyte adherence and migration via inflammatory cytokines such 
as TNF alpha and IL-1 which induce endothelial cells expression of adhesion molecules. This 
has been shown in patients with systemic lupus erythematosus and rheumatoid arthritis 
(30,31,73). In endothelial dysfunction due to chronic inflammation, monocytes transform 
into macrophages after reaching the intima which then express receptors that accumulate 
lipids forming foam cells. These continue to form fatty streaks which are precursors for 
atheromatous plaques (30).  
 
3) Clinical states: 
It has been generally recognised in Diabetes that hyperglycaemia impairs endothelial 
function. Hyperglycaemia generates advanced glycation end products (AGE) that 
accumulate in the vessel wall and impairs NO activity and therefore endothelial function. 
Once in the wall they can also bind to surface receptors amplifying inflammatory responses, 
as well as then stimulating foam cell production advancing atherosclerosis (27). The 
hyperglycaemic state also generates Reactive Oxidative species that have a direct adverse 
action on soluble Guanylyl cyclase and cyclic GMP Kinase (which mediate smooth muscle 
relaxation) (61,74) 
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Other clinical states known to cause endothelial dysfunction include hypertension 
(activating the endothelin system), infection (such as sepsis mediated by imbalances in 
angiopoietin causing increased vessel permeability), obesity (causing a reduction in NO 
bioavailability due to L-arginine depletion), Vitamin D deficiency (thought to act via 
mechanisms similar to with hypertension) and aging (due to gradual reductions in NO 
availability) (49,75–77). Whilst their direct mechanisms are incompletely understood they 
are thought to increase oxidative stress (61,74,78) which leads to leucocyte adhesion and 
inflammation, lipid deposition, vascular smooth muscle cell proliferation, vasoconstriction 
and platelet aggregation, therefore engaging the progression of atherosclerosis and 
cardiovascular disease (27,30,31). 
 
Clinical Relevance: The implications on prognosis of Endothelial dysfunction: 
There have been studies looking at the prognostic impact of endothelial dysfunction 
independently of other established risk factors for cardiac events. Ahmadi et al (60) 
demonstrated that endothelial dysfunction in the presence of non-obstructive coronary 
artery disease was associated with characteristics of vulnerable plaques when assessed 
using intravascular ultrasound. Over the last two decades studies have demonstrated that 
patients with “unobstructed coronary arteries” (generally luminal stenosis <30-50% of the 
diameter) but with demonstrable endothelial dysfunction have increased cardiac events 
(44,62,79,80).  
In the Women’s Ischaemia Syndrome Evaluation (WISE) study (4), patients with abnormal 
measured coronary dilator responses to intra coronary acetylcholine had less time free of 
cardiovascular events (p=0.004). This was independent of risk factors such as age, 
hypertension, diabetes, hypercholesterolaemia, tobacco use and severity of coronary artery 
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disease and fractional luminal cross-sectional area change. In a systematic review and meta-
analysis involving six studies including 1192 patients with normal or non-obstructed (<50% 
luminal stenosis), Branin et al (41) found that in those patients with epicardial endothelial 
dependent dysfunction, 243(20.4 %) had cardiovascular events with a relative risk of 2.38 
(confidence interval 1.74-3.25).  
 
Given that endothelial dysfunction is an adverse predictor independent of apparent 
epicardial obstruction, this would suggest that patients with normal luminography in the 
context of a good history of angina could still benefit from an assessment of their 
endothelial function as they may still be at risk despite “normal epicardial coronaries”. The 
data would suggest that there is increased morbidity and mortality associated with these 
patients and that there is a positive impact to be made with some additional assessment 
(16,62). Reriani et al (38,81) followed up 457 patients with chest pain and unobstructed 
coronary arteries who had coronary vasoreactivity testing with intracoronary acetylcholine. 
During a mean follow up of 8.4±4.7 years the patients who were diagnosed and treated for 
microvascular dysfunction (mainly with beta blockers, aspirin, lipid lowering drugs and 
nitrates) had higher quality of life indices. Tagliomonte et al (82) demonstrated some 
improvements of transthoracic doppler Coronary Flow Reserve (CFR) in 58 patients with 
unobstructed coronaries with doses of 500mg Ranolazine twice daily, though a weakness of 
the study was that participants with luminal stenoses of up to 70% were included. A small 
double blinded study by Villano et al (83) examined 47 patients with microvascular angina 
and their response to a combination of ivabradine and ranolazine versus a placebo. There 
was no significant difference in endothelial function compared to placebo but the patients 
had better quality of life scores and performed better on exercise stress testing with greater 
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time to ST depression and overall performance durations. ACE inhibitors were shown to 
improve flow mediated dilation (a measure used as a surrogate for endothelial dysfunction) 
in patients with hypertension (37), furthermore there is an established benefit from statin 
therapy in the modulation of endothelial function (84–86). A possible conclusion could be 
that in patients with typical symptoms of angina despite normal coronaries would benefit 
from additional functional testing for reversible ischaemia as a means of guiding treatment.  
 
There are also clinical implications of endothelial function on patients with acute coronary 
syndromes. The “no reflow” phenomenon is defined as slow coronary artery flow (graded 
TIMI 0-2), is seen in 5-10% of patients who present with STEMI and is associated with a 
higher incidence of Major Adverse Cardiovascular Events (MACE) and infarct size on 
Cardiovascular Magnetic Resonance Imaging (CMR). It is a recognised complication following 
restoration of luminal patency , purported to disseminate emboli “downstream” resulting in 
endothelial dysfunction demonstrable with microcirculatory resistance. (87,88) Canine 
models have demonstrated that microvascular injury in the context of ischaemic contributes 
to no reflow phenomenon. (89). Electron microscopy of ‘no reflow’ areas, demonstrated 
swollen intraluminal endothelial protrusions and intraluminal bodies bound to the 
endothelial membrane which seemed to obstruct the capillary lumen. Repeated 
ultrastructural examinations (high magnification cell architecture and biomaterial analysis) 
after repeated occlusions of the dog model coronaries showed increased microvascular 
damage as well as increasing incidences of microvascular obstruction (90). The study of no 
reflow and microvascular dysfunction overlaps with reperfusion injury. Hausenloy et al (91) 
used rat hearts to demonstrate that the initial occlusion causes an interruption of antegrade 
flow which induces the inflammatory cascade causing vasoconstriction as well as platelet 
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aggregation and endothelial oedema associated with the no reflow phenomenon. There 
have been studies concerned with mitigating the no reflow process given that this adversely 
affects outcomes irrespective of infarct size, although there hasn’t been a robust technique 
identified thus far it is clear that the endothelium has a crucial role in this problem (92). 
 
Methodologies for the assessment of Endothelial function 
There are various techniques used to assess endothelial function that utilise either 1) the 
measurement of vasomotor dilatation/constriction following the application of vasoactive 
stimuli or 2) the measurement of a surrogate such as Coronary Blood Flow or vascular 
resistance (summarised in Table 2 below):  
Invasive Approaches: 
Invasive assessment  can be performed during angiography. The gold standard technique for 
assessment of endothelial function is the assessment of coronary flow mediated dilatation 
of the epicardial coronary artery in response to intracoronary infusions of ACH (93,94). The 
luminal diameter is measured in two separate angiographic views and fractional change can 
be calculated from this. This demonstrates proximal compartment responses but this 
measure does not reveal changes to the microcirculation.  
O’Mering et al (3,20) measured intra coronary flow using a Doppler tipped guidewire (0.014-
inch FloWire). The tip of the Doppler wire has a piezoelectric transducer that measures peak 
velocity which is linearly related to blood flow and can be calculated with the vessel cross 
sectional area (45,95).  They measured changes in flow in response to adenosine which acts 
as an endothelium-independent vasomotor agonist, inducing hyperaemia and thus giving an 
estimate of the coronary flow reserve.  
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Cold pressor testing (CPT) is an alternative method for assessing endothelial function. This 
method involves wrapping an ice pack around the forearm or placing it on the patient’s 
forehead for two minutes with angiography then repeated. This works via the pathway of 
sympathetic (and likely also parasympathetic neuro humoral responses) stimulation though 
this it is postulated that it may be more complex than this as direct trials comparing this 
technique with intracoronary acetylcholine have demonstrated a greater effect on coronary 
vessel change with CPT (96,97). In a normal coronary circulation, sympathetic activation 
provokes endothelium dependent vasodilation. However in endothelial dysfunction, the 
increase in metabolically mediated flow is offset by beta adrenergically mediated 
vasoconstriction (98).  
Invasive Approach Non-Invasive Approach 
Vasomotion following IC ACH/GTN 









 [Table 2 – Approaches for the assessment of Endothelial dysfunction] Intracoronary 
Acetylcholine/Glyceryl Trinitrate (IC ACH/GTN) is given via the intracoronary route and 
vasomotion can be measured angiographically  
 
Non-Invasive Approaches: 
There are currently multiple non-invasive approaches which usually involve imaging 
techniques. In studies assessing microvascular function, hyperaemia was elicited by either 
dipyridamole or adenosine through non-endothelial mechanisms (43,62). Techniques for 
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measuring CFR included Transthoracic Doppler ECHO, Stress Positron Emission Tomography 
(PET) and CMR. Transthoracic Doppler ECHO measures blood flow in the mid Left Anterior 
Descending artery imaged using colour doppler with a high frequency ultrasound probe. 
Coronary Blood Flow is measured by the Pulsed Doppler technique. This could be a largely 
applicable method that is widely available and inexpensive however it is operator 
dependent, less accurate and contingent on good Echocardiographic windows in patients 
(99,100). PET allows quantitative measurements of myocardial blood flow using myocardial 
dissemination and radioactivity of isotopes (101). CMR  appears a robust method which  can 
be used to generate a semi quantitative assessment of CFR via the Myocardial perfusion 
reserve index (16,60,102). CMR utilises paramagnetic contrast medium gadolinium to 
measure myocardial blood flow. Compared with PET, CMR has better spatial resolution and 
involves no radiation. However post acquisition processing is more challenging, artefacts 
can be a problem and gadolinium should be used cautiously in patients with renal 
impairment (101). PET and CMR however are not used to assess coronary vasomotor 
function in routine practice due to limited availability and high cost, and are currently 
restricted in the research arena.    
Brachial artery reactivity is another method of assessing endothelium dependent and 
endothelium independent function. Endothelium dependent can be measured using high 
resolution ultrasonography proximal to the ante cubital fossa and measuring the increase in 
the diameter of the brachial artery during reactive hyperaemia evoked by the release of a 
cuff inflated to high pressure on the upper arm (37,79). This can then be repeated after 
administering GTN to measure endothelium independent vasodilation.  
 
Limitations of provocative testing: 
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Whilst the action of acetylcholine contributes to both vasoconstriction and vasodilatation, 
the net change is contingent on the relative smooth muscle cell response. Similarly, 
responses to certain stimuli such as the cold in the “cold pressor testing” may be 
confounded by adrenergic responses. Furthermore, there may be patients in whom there 
are global impairments of smooth muscle cell reaction to nitric oxide in which case impaired 
endothelial function may be misattributed (81,101). 
 
The effect of Percutaneous Coronary Intervention on Endothelial Function 
Percutaneous coronary intervention is a widely adopted strategy for the treatment of 
coronary artery disease which continues to advance based on scientific evidence and new 
developments. Initial strategies over forty years ago involved balloon angioplasty (now 
referred to as “plain old balloon angioplasty” or “POBA”) which were met with great 
enthusiasm but were limited by complications of acute vessel closure and neointimal 
proliferation (103,104). Bare Metal Stents were developed in the late 1980s as scaffold 
structures to prevent vessel closure, however these were limited by potentially fatal stent 
thrombosis (ST) and In Stent Restenosis (ISR)(105). First generation Drug Eluting Stents (DES) 
were subsequently developed aiming to reduce these complications and were heralded as a 
major breakthrough. The drug coating had immunosuppressive properties to prevent the 
aggregation of inflammatory cells at the site of stent implantation to reduce restenosis 
rates. Paclitaxel was one of the initial anti-proliferative agents applied to drug eluting stents 
which has a local mechanism that inhibits the microtubule network  which arrests cell 
proliferation (106,107). Drug eluting stents with the agent Sirolimus (also known as 
Rapamycin) were also developed around a similar time. Sirolimus is a cytostatic agent that 
inhibits serine/threonine-specific protein kinase (mTOR) which also inhibits smooth muscle 
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proliferation. Though further generations of DES showed reduced restenosis rates (65) were 
still also associated with ST events. Drug eluting stents also required prolonged periods of 
dual anti platelet therapy with the greater, associated bleeding risk to the population of 
patients treated with PCI. This led to the development of bioresorbable vascular scaffolds 
(BVS) about ten years ago. BVS were initially heralded as the “fourth revolution in 
interventional cardiology" as they did not require the permanent presence of a metallic 
foreign body within the artery and therefore once the scaffolding disappeared there would 
be restoration of normal coronary luminal anatomy. BVS in humans are reported to resorb 
within three to five years whilst theoretically liberating the artery of the “cage”, reducing 
physiological shear stress and restoring pulsatility, cyclical strain and mechano-transduction 
(108). These have been associated with late scaffold thrombosis and other complications 
that have led to it being licensed for research purposes only (109,110). Drug Coated Balloon 
Angioplasty is a method currently widely used to treat ISR that has been proposed as a 
technique that does not carry the same level of risk of ST or prolonged, mandated anti 
platelet therapy given its absence of scaffold structure (104,111–113). 
There have been various studies looking into the effects of PCI on endothelial function given 
that intuitively, the presence of the stents have an effect on the coronary artery 
endothelium and vasomotion (see Table 3) (14). A mechanism of stent thrombosis includes 
the presence of the scaffold not only causing local inflammatory effects but also attenuating 
endogenous vessel NO levels increasing thrombogenicity of the treated segment (109).  
Author Number of 
patients 
Methods Time scale Result 
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Komaru et al 
(114) 
13 Patients treated with 
POBA for stable 
angina. 
Measured vasomotion 






The “day after” 









25 Patients treated with 
POBA assessed with IC 
ACH 
Three months 




responses at both 




39 Post treatment to their 
LAD artery with POBA 
and BMS with IC ACH 




BMS versus POBA 
(-21.8% ± 4.3 vs. -
9.5% ± 2.8, 
p=0.02) 
Togni et al 
(116) 
25 Treated 11 with BMS 
and 14 with SES 
Angiography during 
exercise 
Six months Exercise induced 
vasoconstriction 
in SES compared 
with BMS 
Kim et al (28) 78 10 received BMS, 36 
received PES and 39 
DES assessed with IC 
ACH. Measured 
responses within 
Six months Vasoconstriction 
with DES even 
proximally and 
distally that was 
worse than BMS 
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stents as well as 
proximally and distally 
Gomez-Lara 
et al (109) 
59 Non diabetic patients 
randomised to either 
BVS or Everolimus DES 
measured response to 
IC ACH 




in BVS than DES 
MAGSTEMI 
(109) 
69 STEMI patients treated 
with BVS versus SES 




BVS versus SES 
[Table 3] Comparison of the studies looking at vasomotion in patients treated with PCI. BMS 
= Bare Metal Stents, BVS = Bioresorbable Vascular Scaffolds, IC ACH = Intracoronary 
Acetylcholine, PES = Paclitaxel Eluting Stents, SES = Sirolimus Eluting Stents 
 
Komaru et al (114) looked at the effect of Plain Old Balloon Angioplasty (POBA) on 
endothelial dysfunction in patients treated for symptoms of stable angina. They used 
substance P to assess endothelial function and vasomotor response. Substance P is a 
neuropeptide that operates as a neuromodulator and neurotransmitter and binds to the 
NK-1 receptor on the vascular endothelium stimulating cyclic GMP (in a fashion like 
acetylcholine) to stimulate nitric oxide release and often vasodilation. This process is 
similarly attenuated in endothelial dysfunction in a fashion much like acetylcholine. (40). 
Komaru et al (114) assessed 13 patients the day after their POBA and again after three 
months. Whilst the day after, they demonstrated a coronary vasoconstrictor response to 
substance P, there appeared to be a more uniform vasodilator response at three months 
with the investigators describing this as a “return to normal”(114). Vassanelli et al (58) 
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looked at 25 patients who received POBA and using intracoronary acetylcholine, 
demonstrating abnormal vasomotor responses in arteries treated with POBA three to six 
months after the initial treatment.  
Caramori et al (115) assessed endothelial dependent vasomotor function in a total of thirty-
nine patients who had LAD treatment with a mixture of interventions including POBA and 
bare metal stents (BMS) at least six months prior. Amongst the patients studied, there were 
12 patients who had been stented with BMS, 15 with POBA and 12 received directional 
atherectomy. Both their treated LAD and untreated Circumflex (LCx) were assessed with 
intracoronary acetylcholine. The LAD constricted significantly more when treated by BMS as 
compared with those treated by POBA (-21.8% ± 4.3 vs. -9.5% ± 2.8, p=0.02). By multiple 
regression analysis, stent implantation was the only significant predictor of LAD constriction 
and therefore endothelial dysfunction (p=0.008). 
Togni et al (116) compared 11 patients treated with BMS and 14 patients treated with 
sirolimus drug eluting stents (DES). They measured luminal diameter change to assess 
coronary vasomotor response to exercise by performing biplane angiography whilst the 
patients were pedalling supine on a bicycle. Both groups were assessed more than six 
months after the initial intervention for de novo coronary lesions. In this study, the 
vasomotion within the stents (both BMS and DES) was minimal. However, in segments at 
intervals 5mm, 10mm and 20mm both proximal and distal to the stents there was exercise-
induced vasoconstriction in the sirolimus eluting stents (SES; -12 ± 4% proximally and -15 ± 
6% distally) versus exercise induced vasodilation in the BMS group (+15 ± 3% proximally and 
+17 ± 4% distally; p<0.001). Togni et al (117) later demonstrated similar findings in Paclitaxel 
eluting stents to SES.  
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The Caramori study (115) showed vasoconstriction in BMS at the maximal doses of 
acetylcholine administered, which was at a much high concentration than used in the other 
studies looking at endothelial dysfunction where vasoconstrictor responses were 
demonstrated in DES at lower doses. This relative response to acetylcholine relates to the 
dose related interaction of effects of acetylcholine causing vasodilatation and 
vasoconstriction with acetylcholine facilitating more vasoconstriction at higher doses 
(118,119). The data would suggest that the anti-proliferative drug had a counterproductive 
effect on endothelial function, with a tendency to encourage vasoconstriction (evidenced by 
the lesser attenuation of endothelial function with BMS).  
Kim et al (28) assessed endothelial function using intracoronary acetylcholine, six months 
after treatment with paclitaxel eluting stents (36 patients) and sirolimus eluting stents (39 
patients) and compared these to coronaries treated with BMS (10 patients). They measured 
coronary vasomotor responses 5mm proximal and 5mm distal to stent implantation. 
Greater vasoconstriction was seen in both DES groups than BMS distally to the stent than 
proximally. Sirolimus eluting stents showed -24.7 ± 16.8% fractional change to maximum 
acetylcholine proximally and -70.9 ±11.5% distally, compared with -23.4±15.7% and 
68.7±12.1% in the Paclitaxel eluting stents and -6.23±8.49% and -21.6±4.04% in the BMS 
group (proximally p=0.09 and distally p<0.001). These data would further suggest a flow 
mediated, deleterious effect (given that the effect was greater distally) of the anti-
proliferative agent on the drug eluting stents when compared with BMS. Fuke et al (120) 
measured native vasomotor responses prior to Sirolimus eluting stent insertion at portions 
proximally and distally to the target lesions and whilst these showed near normal vasomotor 
responses before the stent was implanted– there was significant vasoconstrictor responses 
in these same portions when the patients reattended for their repeat angiography at six 
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months. This study provides further evidence that DES have potential long-term adverse 
effects on local coronary endothelial function.  
 
Kubo et al (121) looked at eighty patients who were treated for angina with DES and 
measured brachial artery flow reactivity one week after treatment with drug-eluting stents 
with the aim of establishing if endothelial dysfunction could be a predictor of risk for in-
stent restenosis. There was no difference in the target lesion revascularisation between 
both groups after a 21-month follow up which showed that low flow mediated dilatation did 
not predict restenosis in the treated segment. Low flow mediated dilation (as a surrogate 
for endothelial dysfunction) was associated with a higher incidence of cardiovascular events 
(a composite cardiac death, coronary revascularisation, critical limb ischaemia and stroke) 
with a hazard ratio of 2.77 (95% CI 1.23-6.19 p=0.01). It was not the presence of DES that 
conferred the worse outcome but the presence of poor brachial flow dilatation, indicating 
that endothelial dysfunction afforded the worse prognosis.  
Bioresorbable Vascular Scaffolds (BVS) were considered with interest, given there would be 
a theoretical restoration of vessel compliance and vasomotor function (108). Gogas et al 
(122) explored vasomotor function in porcine coronary arteries treated by Everolimus 
eluting BVS and Everolimus DES. They looked at contraction responses as well as vessel 
dilatation to Substance P. Endothelial dependent relaxation was tested ex vivo and was 
35.91±24.74% and 1.2±3.79% (p<0.01) in isolated BVS segments versus DES respectively at 
two years after implantation (122). The ABSORB II trial enrolled patients who had de novo 
disease in one or two lesions (in different epicardial vessels) with evidence of myocardial 
ischaemia and were randomised to receive either Everolimus eluting BVS or Everolimus DES 
(123). They randomised 501 patients and measured vasomotion using only intracoronary 
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nitrate. This could be seen as a disadvantage as the resultant vasodilatation would reflect 
more the smooth muscle NO capacity rather than giving an account of endothelial response. 
The vasomotor reactivity was not statistically different at three years (0.047mm [SD ±0.109] 
in BVS versus 0.056mm [SD ±0.117] in the DES group p=0.49).  
Gomez-Lara et al (124) studied vasomotor function in 59 non diabetic patients who were 
randomised to either BVS or Everolimus DES. These patients were re-evaluated at 13 
months following implantation. Vasomotor testing showed a vasoconstrictor response to 
intracoronary acetylcholine in 75.6% proximally and in 72.2% distally to the peri-scaffold 
segments. There was no significant difference between the two devices, however BVS has 
more pronounced in-scaffold vasoconstriction than the Everolimus DES (60% versus 27.6%; 
p<0.05). The VANISH trial (98) 60 patients with single vessel disease were randomised to 
receive a Everolimus BVS or DES and they were evaluated one month, one year and three 
years with Cardiac PET scans using CPT to measure Myocardial blood flow and Coronary 
Flow reserve. Coronary Flow reserve was actually lower at three years follow up than at one 
month or one year, implying that neither technique restores vasomotor function (98). The 
MAGSTEMI Randomised control trial (109) measured vasomotor function in 69 patients 
treated for STEMI who were randomised to receive a Magnesium based BVS (with a short 
resorption period <1year) or Sirolimus DES. In those receiving a BVS there was a more 
pronounced vasoconstrictive response to intracoronary acetylcholine compared to the DES 
(-8.1±3.5% versus -2.4±1.3% p=0.003)(109,125).  
Whilst OCT assessment of coronaries treated by BVS have shown favourable indications 
when compared with DES, BVS appears not to offer an advantage in maintaining positive 
coronary vasomotion (110,123,126). In fact, there appears to be enhanced vasoconstriction 
in the lesions treated with BVS. Previous assessment have suggested that this is in part due 
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to the effects of the resorption process causing inflammation (109,124,127). Furthermore 
BVS has been inhibited by device related factors such as a higher crossing profile (due to 
strut thickness), a lack of suitability in calcified lesions and scaffold dismantling which mean 
now that the European Society Guidelines (2018) do not recommend the use of BVS outside 
of clinical studies (109,128).  
Given the relatively favourable effects of POBA on endothelial function when compared 
with stent/scaffold implantation, it is unfortunate that there is a paucity of study data 
looking at endothelial function in patients treated with drug coated balloon angioplasty 
(DCB). Plass et al (59) were unique in that they compared POBA, BMS, DES and DCB 
angioplasty on porcine coronary arteries. They reviewed vasomotor responses after 
endothelial injury due to angioplasty at five hours, one day and one month using in vitro 
techniques measuring changes in tone by measuring endothelium dependent and 
independent vasoreactivity in milliNewtons (mN) or percentage of luminal diameter change. 
In their assessments, endothelium dependent vasodilation was significantly attenuated five 
hours after PCI. The control vessel dilated by 49.6±9.5%, compared with the POBA treated 
segments which dilated by 9.8±3.7% versus DCB at 13.4±9.2% , BMS at 5.7±5.3% and DES at 
7.6±4.7%. A possible explanation offered for the comparatively favourable responses to the 
balloon-based treatments are that in the initial phases additional NO could be made 
available by the process of microdissections during angioplasty. At one month follow up, 
endothelium dependent vasodilation to substance P was 68.6±10.0% versus 76.0±13.1% 
versus 78.7±18.3% and 33±7.4% in POBA, DCB, BMS and DES respectively (p<0.05). The 
endothelium independent vasodilation (measured as a response to nitric oxide and sodium 
nitroprusside) was profoundly impaired one day post PCI 0.062±0.045Mn versus 
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0.054±0.041Mn and 0.023±0.003mN in DCB, BMS and DES respectively compared with 
controls 0.142±0.047Mn).  
The general trend suggests that the physiological homeostasis between the contractile and 
vasodilatory capacities of the treated vessels was greater attenuated in the presence of 
stents. Furthermore, DCB angioplasty may confer some advantageous effects with respect 
to endothelial function. The evidence to date suggests that by comparison, drug eluting 
stents have significant vasoconstrictor responses to acetylcholine suggestive of quite 
marked endothelial dysfunction when compared with BMS. Furthermore, it would seem 
that BMS is detrimental to vasomotor function when compared with POBA. It would appear 
therefore that DCB may be a way of bridging the gap in allowing for more preserved 
endothelial function and vasomotor responses whilst maintaining the benefit of an anti-
proliferative in the shorter term to reduce restenosis rates. It is clear that more data, 








The coronary circulation is a diverse and multi-faceted system that whilst incompletely 
understood is being increasingly appreciated in the wider treatment of cardiovascular 
disease. The ongoing evolution in our understanding of the impacts of treatments and 
percutaneous coronary intervention on coronary circulation represent a conceptual shift 
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from the “modus operandi” of ensuring epicardial luminal patency; which may have guided 
PCI in the past, lending itself to a more comprehensive approach to treating coronary artery 
disease. Whilst there has been an exuberant uptake of intravascular imaging guided PCI, it is 
clear that there is data to suggest that there are multifarious functional and physiological 
indicators that warrant examination as they clearly impact on the patient’s outcomes. At 
present, crucial gaps remain in the greater understanding of coronary artery disease that 
demand further research and deliberation in order to guide the best possible treatment for 
patients in the longer term.  
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